EMA Authorised: Febuxostat Viatris (previously Febuxostat Mylan) (febuxostat) — Viatris Limited

View source ↗

Summary

The EMA authorised Febuxostat Viatris (febuxostat) by Viatris Limited for hyperuricemia and gout, including gouty arthritis indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Gouty Arthritis
• Hyperuricemia

Drugs mentioned

• Febuxostat Viatris (febuxostat)

Snippet

Status: Authorised. Therapeutic area: Hyperuricemia;Arthritis, Gouty;Gout. MAH: Viatris Limited. Decision date: 10/07/2025